Latest News & Blog

Inspiring & original thinking. And, the latest news about us.

THINKING

Welcome to Well Filtered™

A blog series dedicated to unearthing the ideas, perspectives, and innovations that matter most in kidney health.

Is there real value in value-based care? 02.08.22

A SPECIAL, NEW YEAR INVESTIGATIVE BLOG: Making Sense of Population Health, Precision Medicine & Value-Based Care with Mount Sinai’s Dr. Arshad Rahim 01.06.22

An “Inside Look” at Precision Medicine, Cardiovascular & Kidney Disease: We Get It Straight from Bayer’s, Dr. Amit Sharma 10.26.21

A “How To” Playbook for Disrupting Kidney Care: Our Live Chat with the National Kidney Foundation’s Chief Medical Officer 09.20.21

Are Kidney-Focused Clinical Studies Finally Hitting Their Groove? The Trials to Watch & Why 08.10.21

3 Ways We’re Translating Lessons Learned in Cancer to Help Fix the Kidney Care Model 7.27.21

6 Tipping Point Innovations in Kidney Care: A Leading Expert Shares His POV 6.28.21

Why a Shift in Thinking from Kidney Disease to Kidney Health is Mission-Critical. A Candid Conversation with NKF’S Former President & Board Member, Holly Kramer. 6.02.21

NEWS

Renalytix AI plc (“RenalytixAI” or the “Company”) Full Year Report 10.27.20
NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces its full

Read More
RenalytixAI To Announce Financial Results for Full Year Ended June 30, 2020 and Provide Corporate Update 10.16.20
Renalytix AI plc ("RenalytixAI" or the "Company") Notice of results Analyst and Investor presentations NEW YORK , Oct. 16, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management

Read More
RenalytixAI Receives California Commercial Laboratory Certification 09.22.20
RenalytixAI is now currently licensed to provide KidneyIntelX testing services for patients in 49 states NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Renalytix AI, Inc. (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical

Read More
RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System 09.18.20
NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the

Read More
RenalytixAI Files Submission Seeking U.S. FDA Clearance of KidneyIntelX 08.26.20
NEW YORK, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that it

Read More
RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease 08.21.20
Parties to adopt multi-phase approach to develop precision medicine strategies to optimize treatment of cardiovascular, renal and metabolic disease NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), today announced a collaboration with AstraZeneca

Read More
KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients 08.03.20
Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19 Mount Sinai-Led Study to Assess 4,000 Surviving COVID-19 Patients NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Mount Sinai Health System and Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), announce the initiation of a

Read More
RenalytixAI Announces Over Allotment Option Exercise Raises an Additional US$10.9M 07.27.20
NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower

Read More
RenalytixAI Announces Closing of Global Offering and Resulting Total Voting Rights 07.21.20
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower

Read More
RenalytixAI Announces Pricing of Global Offering and Approval to List on the Nasdaq Global Market 07.16.20
NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs,

Read More